Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Theratechnologies Inc. (T:TH)

Business Focus: Biopharmaceuticals

INK Edge Outlook

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for TH within the last 6 months
See all filings within the past 6 months

Company News

Oct 26, 2022 07:30 ET
Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies reports data from a tissue microarrays (TMAs) study...
Read full article
Oct 13, 2022 07:30 ET
Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Nov 15, 202258,2181,759
Oct 31, 202256,459-54,294
Oct 15, 2022110,753-61,896
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Theratechnologies Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. The Company commercializes two medicines in human immunodeficiency viruses (HIV) and has research programs in non-alcoholic steatohepatitis (NASH), Oncology and HIV. Its medicines include Trogarzo, EGRIFTA SV, and EGRIFTA. Trogarzo (ibalizumab-uiyk) is a monoclonal antibody which binds to domain 2 of the cluster difference 4 (CD4) T cell receptors. In the United States, Trogarzo is developed for the treatment of HIV-1 infection. EGRIFTA SV (tesamorelin for injection) and EGRIFTA are developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Its oncology pipeline includes TH1902 and TH1904. Its Non-alcoholic fatty liver disease (NAFLD) pipeline includes Tesamorelin F8. TH1902 is being evaluated in a Phase I clinical trial.

See business summary



Search (past week) for $TH.CA

  • No tweets found